C7R.CD30.CAR-EBVST cells
Phase 1Biologic
C7R.CD30.CAR-EBVST cells is one of 59 biologic programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
109 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Rituxan
RochePhase 3
Oncovin
Eli LillyPhase 3
Polivy
RochePhase 3
Adriamycin
PfizerPhase 3
Gemzar
Johnson & JohnsonPhase 3
Gazyva
RochePhase 3
Oncovin
Eli LillyPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for C7R.CD30.CAR-EBVST cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- BBaylor College of Medicine